180 related articles for article (PubMed ID: 1716334)
1. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
[TBL] [Abstract][Full Text] [Related]
2. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
4. MACOP-B vs F-MACHOP in the treatment of high-grade non-Hodgkin's lymphomas.
Tura S; Mandelli F; Mazza P; Pileri S; Gherlinzoni F; Bocchia M; Zinzani PL; Fiacchini M; Martelli M; Papa G
Leukemia; 1991; 5 Suppl 1():74-8. PubMed ID: 1716338
[TBL] [Abstract][Full Text] [Related]
5. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
7. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
[TBL] [Abstract][Full Text] [Related]
9. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas].
Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M
Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289
[TBL] [Abstract][Full Text] [Related]
10. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
11. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
12. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
13. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ
Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651
[TBL] [Abstract][Full Text] [Related]
14. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE; Hoskins P; Klimo P; Connors JM
Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
[TBL] [Abstract][Full Text] [Related]
15. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
16. ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher RI; Young RC; Longo D; DeVita VT
Semin Oncol; 1985 Mar; 12(1 Suppl 2):29-32. PubMed ID: 2579441
[TBL] [Abstract][Full Text] [Related]
17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
